PTC Therapeutics

PTCT

Market cap $6.09B

WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors.

WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 17,515 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees.

PTC Therapeutics, Inc. (PTCT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

PTC Therapeutics, Inc. (PTCT) Presents at Leerink Global Healthcare Conference 2026 Transcript

Added 41,303 shares of PTC Therapeutics; estimated trade size $3.00 million based on quarterly average pricing Quarter-end position value increased by $15.72 million, reflecting both share purchases and price movement Trade represented a 0.42% change in 13F reportable assets under management Post-trade stake: 903,916 shares valued at $68.66 million PTC Therapeutics now represents 9.56% of fund AUM, which places it outside the fund's top five holdings

WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026 Monday, March 2 at 9:50 a.m.

PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for Huntington's disease and Vatiquinone for Friedreich's ataxia, offer significant upside but carry clinical trial risks. PTCT's competitive edge lies in its oral small molecule platform, collaborative development model, and strong pricing power in ultra-rare disease markets.

PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.